ABMD:NGS-ABIOMED Inc.

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 260.58

Change

-2.11 (-0.80)%

Market Cap

USD 4.82B

Volume

0.36M

Analyst Target

USD 337.22
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Abiomed Inc is engaged in providing mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+2.48 (+1.89%)

USD 51.34B
ALGN Align Technology Inc

+11.06 (+3.68%)

USD 22.65B
BRKR Bruker Corporation

+4.41 (+5.65%)

USD 12.93B
SWAV Shockwave Medical Inc

-0.06 (-0.02%)

USD 12.34B
PODD Insulet Corporation

+2.85 (+1.73%)

USD 11.49B
MASI Masimo Corporation

+2.63 (+1.96%)

USD 7.14B
AXNX Axonics Modulation Technologie..

-0.37 (-0.55%)

USD 3.41B
IRTC iRhythm Technologies Inc

+2.72 (+2.39%)

USD 3.36B
QDEL Quidel Corporation

+1.32 (+3.38%)

USD 3.14B
LIVN LivaNova PLC

+1.01 (+1.87%)

USD 3.02B

ETFs Containing ABMD

CHEP 0.00 % 1.12 %

N/A

N/A
LALT Invesco Multi-Strategy Al.. 0.00 % 0.88 %

+0.02 (+0%)

USD 6.53M
MOM 0.00 % 1.88 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.83% 31% F 15% F
Dividend Return N/A N/A N/A N/A F
Total Return -19.83% 31% F 15% F
Trailing 12 Months  
Capital Gain -37.77% 43% F 24% F
Dividend Return N/A N/A N/A N/A F
Total Return -37.77% 43% F 23% F
Trailing 5 Years  
Capital Gain 944.83% 97% N/A 99% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 944.83% 97% N/A 99% N/A
Average Annual (5 Year Horizon)  
Capital Gain 84.28% 93% A 91% A-
Dividend Return 84.28% 93% A 91% A-
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 75.73% 19% F 20% F
Risk Adjusted Return 111.30% 94% A 95% A
Market Capitalization 4.82B 99% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 120.60 54% 22%
Price/Book Ratio 12.55 13% 9%
Price / Cash Flow Ratio 0.00 3% 10%
Price/Free Cash Flow Ratio 0.00 3% 2%
Management Effectiveness  
Return on Equity 31.85% 98% 95%
Return on Invested Capital N/A N/A N/A
Return on Assets 15.20% 98% 98%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector